Features | Partner Sites | Information | LinkXpress
Sign In
Fluke Biomedical
GLOBETECH PUBLISHING
Ampronix

Zoll Acquires Intellectual Assets of Coaxia

By HospiMedica International staff writers
Posted on 15 Jul 2013
ZOLL (Chelmsford, MA, USA) has purchased the assets of CoAxia (Maple Grove, MN, USA), an early revenue stage medical device company that provides catheter-based perfusion augmentation therapies.

The core application ofCoAxia’s catheter technology, distributed under the trade names NeuroFlo and FloControl, involves the redistribution of blood flow from the lower extremities to support brain function during cerebral ischemia resulting from vasospasm, following subarachnoid hemorrhage. CoAxia did not have the funds to continue development after its de novo petition for the NeuroFlo catheter was rejected by the US Food and Drug Administration (FDA) for acute ischemic stroke. Zoll, however, still sees opportunity for the device and plans to design a new pivotal trial to take before the FDA.

Both NeuroFlo and FloControl blood flow redistribution technology use dual balloons to create temporary partial obstruction in the descending aorta. This technique causes a redistribution of cardiac output from the lower extremities to the cerebral vasculature without significantly increasing arterial blood pressure. The acquisition of the intellectual property also includes several key patents on cerebral perfusion augmentation as well as numerous other patents relevant to other various vascular procedures. Financial terms of the purchase were not disclosed.

“NeuroFlo technology has the potential to address a large portion of the population who suffer cerebral ischemia, offering a significant benefit to patients and the healthcare system,” said James Palazzolo, president of Zoll. “Our task is to continue to develop the significant body of clinical evidence started by CoAxia demonstrating the safety and efficacy of the NeuroFlo catheter and, in the end, do what is necessary for it to be a standard treatment option for hundreds of thousands of stroke patients worldwide.”

The acquisition of CoAxia’s intellectual property also offers synergy with Zoll’s acute critical care portfolio of products such as temperature management, which may reduce reperfusion injury following ischemia by using balloon catheters. The devices could also offer significant potential applications in blood flow redistribution for trauma, cardiac arrest, coronary procedures, surgical blood loss, and renal perfusion.

Related Links:

ZOLL
CoAxia



MinXray
Bovie Medical
Centurion Service

Channels

Critical Care

view channel
Image: The Trellis peripheral infusion system (Photo courtesy of Covidien).

Thrombolytic Drug Delivery Device Dissolves Blood Clots

A redesigned peripheral infusion system enables focused treatment of blood clots to avoid potential post-thrombotic syndrome (PTS). The updated Trellis peripheral infusion system is a pharmacomechanical... Read more

Surgical Techniques

view channel
Image: The Optimis Fusion integrated laser platform (Photo courtesy of Quantel Medical).

Combination Laser Platform Treats Glaucoma and Cataract

An integrated laser offers ophthalmologists a versatile armamentarium for treating both cataract and glaucoma in an efficient combination platform. The Optimis Fusion integrated laser combines advanced... Read more

Women's Health

view channel
Image: A prototype contraceptive implant (Photo courtesy of MicroCHIPS).

Contraceptive Implant Hails New Era of Birth Control

A fingernail-sized implant holds enough 30-microgram daily doses of levonorgestrel to provide contraception for 16 years. Developed by MicroCHIPS (Lexington, MA, USA), a MIT (Cambridge, MA, USA) startup,... Read more

Health IT

view channel

Wikipedia Dominates Internet Drug Information

Wikipedia, along with Google and WebMD, is where more than half of all Americans turn to for health information on prescription drugs. Researchers at the Blackstone Group (London, United Kingdom), Harvard Medical School (Boston, MA, USA), and other institutions selected new drug-safety communications related to prescription... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.